These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26171215)

  • 1. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
    Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
    Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
    Fan Q; Lv W; Xu Y; Dong Y; Xiang Z; Wang J
    Curr Pharm Des; 2020; 26(26):3171-3186. PubMed ID: 32067605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.
    Liu L; Zhang Y; Wei J; Chen Z; Yu J
    J Cancer; 2019; 10(4):799-809. PubMed ID: 30854085
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
    Sakharkar P; Kurup S; Deb S; Assaad K; Gesinski D; Gayle EJ
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials.
    Li J; Huang S; Zheng W; Ding H; Zhang Y; Huang S; Zhang Z; Chen B; Liang Z; He G; Xiao X; Li S; Xu T; Chen X
    Curr Med Res Opin; 2013 Dec; 29(12):1691-9. PubMed ID: 23981081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
    Wang S; Yang Z; Wang Z
    Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
    Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
    Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.
    Botrel TEA; Clark LGO; Paladini L; Clark OAC
    BMC Cancer; 2016 Aug; 16(1):677. PubMed ID: 27558497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
    Cao Y; Tan A; Gao F; Liu L; Liao C; Mo Z
    Int J Colorectal Dis; 2009 Jun; 24(6):677-85. PubMed ID: 19184059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.
    Sakharkar P; Kurup S
    Diseases; 2023 Oct; 11(4):. PubMed ID: 37873790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.